Puma Biotechnology Inc (PBYI) : The most positive equity analysts on Puma Biotechnology Inc (PBYI) expects the shares to touch $70, whereas, the least positive believes that the stock will trade at $36 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $55.33 with an expected fluctuation of $17.47 from the mean.
Puma Biotechnology Inc (PBYI) : 5 analysts are covering Puma Biotechnology Inc (PBYI) and their average rating on the stock is 2.2, which is read as a Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Puma Biotechnology Inc (NYSE:PBYI): The stock opened at $59.16 on Thursday but the bulls could not build on the opening and the stock topped out at $61.24 for the day. The stock traded down to $55.65 during the day, due to lack of any buying support eventually closed down at $58.71 with a loss of -0.74% for the day. The stock had closed at $59.15 on the previous day. The total traded volume was 920,504 shares.
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.